Version history

{
  "description": "How can DNA methylation clocks, histone modification patterns, and epigenetic age acceleration serve as biomarkers for Alzheimer disease, Parkinson disease, and related neurodegenerative conditions?\n\nFocus areas:\n1. Diagnostic biomarker utility: Can epigenetic clocks distinguish AD from other dementias? What is the sensitivity/specificity?\n2. Prognostic value: Does epigenetic age acceleration correlate with disease progression, cognitive decline rate, or conversion from MCI to AD?\n3. Biomarker validation: What blood, CSF, or tissue samples are available for validation? Which clock algorithms (Horvath, Hannum, PhenoAge, GrimAge) perform best?\n4. Mechanistic links: How do epigenetic changes relate to tau pathology, amyloid burden, alpha-synuclein, TDP-43, and other neurodegenerative hallmarks?\n5. Confounding factors: How do comorbidities (vascular disease, diabetes), lifestyle, and cell type composition affect epigenetic biomarker readings?\n\nThe existing gap on therapeutic approaches (gap-v2-bc5f270e) addressed epigenetic clock modulation as therapy. This gap focuses specifically on biomarker development and validation for diagnosis, prognosis, and disease monitoring.",
  "domain": "neurodegeneration",
  "status": "resolved",
  "priority_score": 0.85,
  "market_price": 0.5
}